Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?

On August 6, Harrow, Inc. announced a definitive agreement to acquire Tyrvaya nasal spray from Viatris Inc. for up to $100 million. The deal terms outline a $30 million cash payment at closing, funded by Harrow's cash reserves, with up to $70 million in contingent sales milestone payments contingent upon future sales. The transaction, expected to close in the second half of 2026, transfers the dry eye disease treatment, approved in the U.S., China, and Taiwan, to Harrow, a specialized ophthalmic player.

This allows Viatris to streamline its portfolio. Harrow's Q2 2026 results show accelerating operational momentum with revenue up 60% sequentially and 11% year-over-year to $70.7 million, driven by its flagship dry eye drug VEVYE and strong demand for other products. Despite a GAAP net loss of $17.3 million and negative Adjusted EBITDA of $1.2 million, Harrow reiterated its ambitious full-year revenue and Adjusted EBITDA guidance.

Viatris, operating at a much larger scale, reported $3.8 billion in total revenues and $1.2 billion in Adjusted EBITDA in Q2 2026, prompting a mid-year guidance raise. Management cited a $177.8 million non-cash impairment charge on the Tyrvaya divestment as a factor in the GAAP net loss. The transaction builds Harrow's comprehensive North American dry eye portfolio and projects over $30 million in Tyrvaya revenue by 2027.

However, the upfront $30 million cash outlay strains Harrow's liquid cash reserves, and the company continues to post GAAP net losses. For Viatris, the deal highlights disciplined capital allocation, robust free cash flow, and a focus on higher-growth pipeline drivers. Institutional positioning shows contrasting trends, with Harrow seeing slight hedge fund consolidation and Viatris gaining institutional support.

The deal reflects two opposing corporate lifecycle strategies, with Harrow scaling into an eye care powerhouse and Viatris pruning non-core assets to fortify its balance sheet and return cash to shareholders.